To access this element change to forms mode OFF
Grant Award View - GA52656
P3BEP Trial: Accelerating First-Line Chemotherapy to Improve Cure Rates...
GA ID:
GA52656
Agency:
Cancer Australia
Approval Date:
8-May-2019
Publish Date:
3-Jul-2019
Category:
Cancer
Grant Term:
30-Jun-2019 to 29-Jun-2022
Value (AUD):
$600,000.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
CA 18/19 Improved cancer control
Grant Program:
2018 Priority-driven Collaborative Cancer Research Scheme
Grant Activity:
P3BEP Trial: Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours: An Australian-Led, International Randomised Trial
Purpose:
Advanced germ cell tumours such as testicular cancer typically affect young people, and more than half of those with the worst prognosis features die with standard treatment. The purpose of this study is to determine whether giving the same dose of a chemotherapy combination called BEP, Bleomycin, Etoposide and Cisplatin, on a 2-weekly schedule will be more effective than a 3-weekly schedule. This Australian led international trial could improve cure rates and reduce the duration of side effects.
GO ID:
GO Title:
2018 PdCCRS Project Grants for funding commencing 2019
Internal Reference ID:
2018 PdCCRS
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
University of Sydney
Recipient ABN:
15 211 513 464
Grant Recipient Location
Suburb:
Sydney
Town/City:
Sydney
Postcode:
2006
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
National
Postcode:
Multiple
Country:
AUSTRALIA